Key result
Managing coronary no-reflow during PCI requires combined prevention, local vasodilators, and antiplatelet therapy.
Why the study?
Coronary no-reflow complicates percutaneous coronary interventions, dampening the benefits of primary PCI, and is associated with poor short-term and long-term prognosis.
This review provides a comprehensive overview of the diagnosis, prevention, and management strategies for coronary no-reflow during percutaneous coronary intervention.
Answers are grounded in this paper and cite their sources.
Supports integrated no-reflow strategies in PCI; leaves open randomized trials to define optimal combinations.
Coronary no-reflow (NR) defined as inadequate myocardial perfusion despite restoration of coronary artery patency is a bane for an interventional cardiologist. It can complicate percutaneous coronary interventions especially in the setting of STEMI and dampens the potential benefits of PPCI. Broadly classified as Reperfusion NR and Interventional NR, mechanism is multifactorial. The basic underlying culprit is microvascular obstruction either secondary to distal embolization, intravascular plugging, or ischemic reperfusion injury. Coronary angiogram is an easy, readily available, and essential modality to diagnose no-reflow, but the gold standard is gadolinium-enhanced cardiovascular magnetic resonance imaging. Preventive strategies for NR should be integral part of prePCI planning especially in clinical scenario where NR is expected such as STEMI with delayed presentation and high thrombus burden, atherectomy, and SVG PCI. The cornerstone of treatment for NR is local vasodilators and antiplatelet therapy to ameliorate vasospasm and thromboembolism respectively, and different combinations of the two should be used in no specific order to achieve reversal of NR. NR phenomenon is associated with poor short-term and long-term prognosis and every attempt should be made to avoid or reverse it. Therapeutic hypothermia, hyperoxemic reperfusion therapy, targeted anti-inflammatory approach, and cellular approach appear proising but further research is mandatory.
No takes yet. Share an insight, caveat, or question.
Lalita Nemani (2023) conducted a review in Coronary no-reflow. Coronary no-reflow is a multifactorial complication of percutaneous coronary interventions that requires a combination of preventive strategies, local vasodilators, and antiplatelet therapy for management.
Synapse has enriched 10 related papers. Consider them for comparative context: